Amanta Healthcare Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹910 Cr
- P/E
- 49.65
- ROE
- 10.34%
- PEG
- 0.44
- Price to sales
- 3.00
- Debt to equity
- 0.89
- 52W high / low
- ₹234 / ₹95.0
- Sales growth (5Y)
- 10.93%
- EBITDA margin
- 20.45%
- Net profit margin
- 5.69%
- Promoter holding
- 63.80%
- Sales (last year)
- ₹303 Cr
Guidance scorecard · Q2 FY27 call
What Amanta Healthcar's management guided
RevenueQ2 FY27 call
20–40%- FY '28 top line target: INR 400-420 crore, including SVP line contribution.
- SVP (Small Volume Parenterals) line expected to start in Q1 FY '28 with gradual utilization ramp-up to 45-50% by first two quarters.
- New SVP line aimed at inhalation and ophthalmic products; 20-product pipeline with 12 in SVP segment.
- SteriPort Line 3 operational since September, expected to contribute INR 60 crore in FY '27; full capacity utilization from November 20.
- Long-term growth strategy targets 20%+ CAGR revenue growth and 25%+ EBITDA margin.
- Expansion driven by increased capacity, product development, and geographical market deepening including India, Australia, Canada, South Africa, and parts of Europe.
2 more points from Amanta Healthcar's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Amanta Healthcar said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- The company has recently commissioned SteriPort Line 3 (Sept 2026) with full capacity utilization expected by Nov 20, 2026.
- The next major CapEx is for the SVP (Small Volume Parenterals) facility expansion, targeted to be operational in Q1 FY 2028.
- Post SVP expansion, future CapEx will focus mainly on product development (20 products in pipeline, especially inhalation and ophthalmic portfolios) and plant automation to reduce manpower and improve efficiency.
- Annual CapEx after SVP is expected to be between INR7-20 crore, primarily for product pipeline, dossiers, regulatory filings, and automation.
- No immediate plan for further CapEx in SteriPort beyond existing capacity (12 crore bottles/year).
2 more points from Amanta Healthcar's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
PlannedSee what Amanta Healthcar said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
- The company expects steady order inflow, supported by new capacity coming online.
- SteriPort Line 3, commissioned in September 2026, is ramping up and expected to contribute about INR60 crore in top line for FY '27.
- The SVP line, expected to be commissioned by Q1 FY '28, targets inhalation and ophthalmic products, with a product pipeline of 20, of which 12 are for SVP.
- Utilization of SVP line expected to be around 40%-50% in initial quarters post-commissioning, with conservative revenue guidance of INR16 crore for FY '27-28, potentially up to INR35-60 crore depending on product mix.
2 more points from Amanta Healthcar's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Amanta Healthcare latest results (Sep 2026)
Revenue
₹83 Cr
+17.27% YoY
Net profit
₹5 Cr
+302% YoY
Operating margin
20.68%
EPS
₹1.25
Amanta Healthcare shareholding (Sep 2026)
Promoters
63.80%
+0.01 pp QoQ
FIIs
0.07%
−0.36 pp QoQ
DIIs
12.20%
−0.72 pp QoQ
Public
23.93%
+1.09 pp QoQ
Amanta Healthcar announcements
All announcements →- Capex / expansionMajor developmentAmanta Healthcare Limited reports Q2 & H1 FY27 financial results with revenue growth
Financials of Amanta Healthcar
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Amanta Healthcar
Shareholding breakup across reporting periods.
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Promoters + | 63.56% | 63.56% | 63.72% | 63.79% | 63.80% |
| FIIs + | 1.00% | 1.10% | 0.85% | 0.43% | 0.07% |
| DIIs + | 11.34% | 11.24% | 12.88% | 12.92% | 12.20% |
| Public + | 24.10% | 24.09% | 22.55% | 22.84% | 23.93% |
| No. of Shareholders | 18,669 | 16,181 | 15,222 | 12,612 | 12,319 |
Financials of Amanta Healthcar
Quarterly Results
Quarter-by-quarter operating performance
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 68.10 | 66.73 | 67.81 | 72.06 | 65.31 | 70.89 | 74.49 | 76.99 | 68.80 | 83.13 |
| YoY Sales growth | -4.10% | +6.23% | +9.85% | +6.84% | +5.34% | +17.27% | ||||
| Expenses + | 54.70 | 52.85 | 52.75 | 53.10 | 50.41 | 56.24 | 59.13 | 62.03 | 54.26 | 65.94 |
| Operating Profit | 13.40 | 13.88 | 15.06 | 18.96 | 14.90 | 14.65 | 15.36 | 14.96 | 14.54 | 17.19 |
| OPM % | 19.68% | 20.80% | 22.21% | 26.31% | 22.81% | 20.67% | 20.62% | 19.43% | 21.13% | 20.68% |
| Other Income + | 0.15 | 0.21 | 0.87 | 0.16 | 0.96 | -2.56 | 0.68 | 1.66 | 0.64 | 0.76 |
| Interest | 9.45 | 6.32 | 5.90 | 6.28 | 6.29 | 5.15 | 5.06 | 4.25 | 6.00 | 5.84 |
| Depreciation | 4.60 | 4.60 | 4.51 | 4.69 | 4.64 | 4.66 | 4.67 | 4.75 | 4.69 | 5.28 |
| Profit before tax | -0.50 | 3.17 | 5.52 | 8.15 | 4.93 | 2.28 | 6.31 | 7.62 | 4.49 | 6.83 |
| Tax % | -28.00% | 28.71% | 22.64% | 26.87% | 28.80% | 46.93% | 26.47% | 27.43% | 26.28% | 28.84% |
| Net Profit + | -0.36 | 2.26 | 4.28 | 5.96 | 3.51 | 1.21 | 4.63 | 5.53 | 3.31 | 4.86 |
| EPS in Rs | -0.13 | 0.78 | 1.48 | 2.07 | 1.22 | 0.31 | 1.19 | 1.42 | 0.85 | 1.25 |
Financials of Amanta Healthcar
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 184 | 171 | 225 | 259 | 280 | 275 | 288 | 303 |
| Sales growth | -7% | +32% | +15% | +8% | -2% | +5% | +10% | |
| Expenses + | 147 | 133 | 173 | 206 | 223 | 215 | 228 | 241 |
| Operating Profit | 37 | 38 | 52 | 53 | 58 | 60 | 60 | 62 |
| OPM % | 20% | 22% | 23% | 20% | 21% | 22% | 21% | 20% |
| Other Income + | 2 | 1 | 76 | 4 | 1 | 1 | 1 | 4 |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 21 | 21 |
| Depreciation | 16 | 17 | 17 | 18 | 20 | 18 | 19 | 19 |
| Profit before tax | -15 | -18 | 62 | 3 | 5 | 15 | 21 | 25 |
| Tax % | 25% | 23% | 11% | 179% | 32% | 29% | 30% | |
| Net Profit + | -19 | -22 | 55 | -2 | 4 | 10 | 15 | 18 |
| EPS in Rs | -7.03 | -8.14 | 20.54 | -0.79 | 1.35 | 3.64 | 3.83 | 4.71 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Amanta Healthcar
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 27 | 27 | 27 | 27 | 29 | 39 | 39 |
| Reserves | 2 | -20 | 36 | 36 | 39 | 68 | 181 | 189 |
| Borrowings + | 231 | 235 | 226 | 216 | 211 | 204 | 244 | 204 |
| Other Liabilities + | 127 | 150 | 104 | 96 | 75 | 81 | 93 | 97 |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 | 558 | 529 |
| Fixed Assets + | 244 | 242 | 240 | 232 | 228 | 217 | 207 | 321 |
| CWIP | 0 | 0 | 0 | 9 | 0 | 7 | 82 | 0 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 | 7 | 6 |
| Other Assets + | 144 | 149 | 149 | 133 | 120 | 150 | 262 | 201 |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 | 558 | 529 |
Financials of Amanta Healthcar
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 38 | 31 | 62 | 43 | 58 | 47 | 48 |
| Cash from Investing Activity + | -9 | -13 | -6 | -7 | -10 | -24 | -94 |
| Cash from Financing Activity + | -37 | -18 | -50 | -42 | -46 | -23 | 126 |
| Net Cash Flow | -8 | -0 | 6 | -6 | 1 | -1 | 81 |
| Free Cash Flow | 27 | 19 | 52 | 36 | 46 | 26 | -32 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 102% | 66% | 119% | 93% | 111% | 84% | 93% |
Financials of Amanta Healthcar
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 110 | 73 | 75 | 63 | 67 | 55 |
| Inventory Days | 225 | 422 | 338 | 247 | 309 | 464 | 530 |
| Days Payable | 99 | 186 | 185 | 130 | 129 | 194 | 230 |
| Cash Conversion Cycle | 229 | 345 | 226 | 193 | 243 | 336 | 354 |
| Working Capital Days | 51 | -5 | 28 | 42 | 16 | 26 | 6 |
| ROCE % | 9% | 14% | 13% | 14% | 15% | 12% |
Guidance history
How Amanta Healthcar's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Flat | Planned | Planned | — |
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q3 FY26 call → | 20–40% | Flat | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
94 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,938 stocks |
|---|---|---|
| Last 12 months | +97.6% | 92% |
| Last 6 months | +81.2% | 94% |
| Last 3 months | +50.0% | 98% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,938 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Amanta Healthcar: 0.4 × 92 + 0.4 × 94 + 0.2 × 98 = 94.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 13 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Amanta Healthcare: frequently asked questions
What is Amanta Healthcare share price today?
Amanta Healthcare last traded at ₹234.47, with a market capitalisation of ₹910 Cr and a P/E ratio of 49.6.
What were Amanta Healthcare's latest quarterly results?
For the quarter ended Sep 2026, Amanta Healthcare reported revenue of ₹83 Cr (+17.27% year on year) and net profit of ₹5 Cr, with an operating margin of 20.68%.
Is Amanta Healthcare's profit growing?
Net profit was ₹5 Cr in Sep 2026 against ₹1 Cr in Sep 2025, a change of +302%.
What is Amanta Healthcare's EPS?
Amanta Healthcare's earnings per share for the quarter ended Sep 2026 was ₹1.25.
What is the promoter holding in Amanta Healthcare?
Promoters held 63.80% of Amanta Healthcare in Sep 2026 (+0.01 pp versus Jun 2026).
How much do FIIs and DIIs hold in Amanta Healthcare?
In Sep 2026, foreign institutional investors held 0.07% and domestic institutions (including mutual funds) held 12.20% of Amanta Healthcare.
What is Amanta Healthcare's ROE and ROCE?
Amanta Healthcare's return on equity is 10.3% and its return on capital employed is 11.6%.
Does Amanta Healthcare pay a dividend?
Amanta Healthcare's dividend yield is 0% at the current price; see the Amanta Healthcare dividends page for past payouts.
What did Amanta Healthcare's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Amanta Healthcare's management.
How does Arthneeti AI analyse Amanta Healthcare?
Arthneeti reads Amanta Healthcare's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
